Psychedelic Science 2023

Be Part of

        the Breakthrough

Presented by

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind Study to Assess Safety/Efficacy of Inhaled Cannabis in Veterans for PTSD

PS2023-285-tn

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind Study to Assess Safety/Efficacy of Inhaled Cannabis in Veterans for PTSD

Several preliminary studies suggest that cannabis may treat PTSD symptoms. Building off of our previous MJP1 study, this current study aims to re-examine use of inhaled cannabis for treatment of PTSD using a larger sample size, a parallel design, and methods to mitigate placebo response. This Phase 2 multicenter randomized placebo-controlled, double-blind study will assess the safety and efficacy of inhaled cannabis (high THC) versus placebo to manage PTSD symptoms and pain among approximately 360 veterans in an outpatient setting. The study will be conducted in Michigan and three other sites in the U.S.

Share: Phase 2 Multicenter Randomized Placebo-controlled, Double-blind Study to Assess Safety/Efficacy of Inhaled Cannabis in Veterans for PTSD

Facebook
Twitter
LinkedIn
Email

Already Registered?

If you already registered for the in-person portion of the Psychedelic Science 2023 conference, get immediate access to PS2023: The Virtual Trip by logging in with the email address you used when signing up for the conference. We’ll email you a login link—no password necessary!

Need to Register?

If you are not yet registered for Psychedelic Science 2023, you can sign up for PS2023: The Virtual Trip access by creating an account.